Abstract
The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 2416-2419 |
| Number of pages | 4 |
| Journal | Cancer |
| Volume | 56 |
| Issue number | 10 |
| DOIs | |
| State | Published - Dec 1 1985 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Buserelin as primary therapy in advanced prostatic carcinoma. / Presant, C. A.; Soloway, M. S.; Klioze, S. S.; Kosola, J. W.; Yakabow, A. L.; Mendez, R. G.; Kennedy, P. S.; Wyres, M. R.; Naessig, V. L.; Ford, K. S.
In: Cancer, Vol. 56, No. 10, 01.12.1985, p. 2416-2419.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Buserelin as primary therapy in advanced prostatic carcinoma
AU - Presant, C. A.
AU - Soloway, M. S.
AU - Klioze, S. S.
AU - Kosola, J. W.
AU - Yakabow, A. L.
AU - Mendez, R. G.
AU - Kennedy, P. S.
AU - Wyres, M. R.
AU - Naessig, V. L.
AU - Ford, K. S.
PY - 1985/12/1
Y1 - 1985/12/1
N2 - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.
AB - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=0022406964&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022406964&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#
DO - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#
M3 - Article
C2 - 3930064
AN - SCOPUS:0022406964
VL - 56
SP - 2416
EP - 2419
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 10
ER -